Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications
Clinical trials for MET inhibitors have demonstrated limited success for their use in colon cancer (CC). However, clinical efficacy may be obscured by a lack of standardisation in MET assessment for patient stratification. In this study, we aimed to determine the molecular context in which MET is de...
Guardado en:
Autores principales: | Stephanie G. Craig, Svenja Mende, Matthew P. Humphries, Victoria Bingham, Amélie Viratham Pulsawatdi, Maurice B. Loughrey, Helen G. Coleman, Stephen McQuaid, Richard H. Wilson, Sandra Van Schaeybroeck, Jacqueline A. James, Manuel Salto‐Tellez |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0b8be54a07784f57bd958f3c8b5f5b03 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer
por: Zhang Q, et al.
Publicado: (2020) -
Genotype × Environment Interaction in Canola (Brassica napus L.) Seed Yield in Chile
por: Escobar,Magaly, et al.
Publicado: (2011) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021) -
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Karan Seegobin, et al.
Publicado: (2021) -
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)